Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy

Keyphrases

• Clinical Outcomes 100%
• Combination Therapy 100%
• Prognostic Factors 100%
• Clear Cell Renal Cell Carcinoma (ccRCC) 100%
• Immuno-oncology 100%
• Overall Survival 21%
• Tyrosine Kinase Inhibitor 21%
• Liver Metastasis 15%
• No Significant Difference 10%
• Progression-free Survival 10%
• Multivariate Analysis 5%
• Univariate Analysis 5%
• Poor Prognosis 5%
• Clinical Characteristics 5%
• Median Overall Survival 5%
• Median Progression-free Survival 5%
• Karnofsky Performance Status 5%
• Poor Prognostic Factors 5%
• Objective Response Rate 5%
• Heterogeneous Disease 5%
• Inhibitor Combination 5%
• Neutrophil-to-lymphocyte Ratio 5%
• Tyrosine Kinase Inhibitor Therapy 5%
• Comparing Groups 5%
• International Metastatic Renal Cell Carcinoma Database Consortium 5%
• Metastatic RCC 5%

Medicine and Dentistry

• Combination Therapy 100%
• Prognostic Factor 100%
• Oncology 100%
• Immunoglobulin 100%
• Clear Cell Renal Cell Carcinoma 100%
• Overall Survival 26%
• Tyrosine-Kinase Inhibitor 26%
• Progression Free Survival 15%
• Liver Metastasis 15%
• Multivariate Analysis 5%
• Univariate Analysis 5%
• Karnofsky Performance Status 5%
• Kidney Metastasis 5%
• Lymphocyte 5%
• Diseases 5%
• Neutrophil 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunoglobulin 100%
• Combination Therapy 100%
• Renal Cell Carcinoma 100%
• Protein Tyrosine Kinase Inhibitor 26%
• Overall Survival 26%
• Progression Free Survival 15%
• Liver Metastasis 15%
• Kidney Metastasis 5%
• Diseases 5%